,5 However, a number of studies also suggested that PPARɣ agonists have direct renoprotective effects in experimental diabetes.6, 7, 8 Moreover, PPARɣ agonists have also been suggested to be renoprotective in several (experimental) non-diabetic glomerular diseases, for example, human focal segmental glomerulosclerosis.9, 10, 11, 12, 13. Here, PPARA is linked to glomerular disorder.